Vijay Pande is betting on AI-native biotech startups through his new fund, VZVC. The former a16z biotech leader argues biology is now an engineering discipline, but clinical trials stay prohibitively expensive. He believes open, shared datasets, not walled-off ones, will unlock AI's potential in medicine.
Opening Kapyn…